Huckman's Drug Headlines

Lots of late news from the drug makers. CNBC’s Mike Huckman has the latest.

There are 3 big pieces of information that Mike Huckman feels investors should know about. They follow:

Eli Lilly

Eli Lilly (LLY) is halting patient enrollment in 2 small clinical trials for Prasugrel, a blood-clotting drug that would have competed with Plavix. The company isn’t giving many details and Huckman adds that investors are spooked by the news.

Amgen

Sales of Amgen’s (AMGN) top-selling drug Aransep fell 23%. Now, Amgen’s only great hope is a late stage developmental drug for osteoperosis says Huckman. The “make or break” data is due out sometime next year.

> Read more about Amgen Q3 earnings

Cephelon

There’s a new FDA warning on a potentially fatal skin rash that develops as a side effect from a Narcolepsy drug made by Cephelon (CEPH). Huckman suggests CEPH could trader lower on this news.

______________________________________________________
Got something to say? Send us an e-mail at [e-mail] and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to [e-mail].

Trader disclosure: On Oct 24, 2007, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Macke Owns (DIS), (INTC), (ATVI), (YHOO) (EMC); Najarian Owns (C), (DISH), (EMC), (MSFT), (YHOO), (SNDK), (GOOG); Finerman Owns (GS); Finerman's Firm Owns (ASD), (BIIB), (CTX), (MSFT), (NYX), (NMX), (TGT), (WMT), (PLCE), (MO), (C); Finerman's Firm Owns S&P 500 Puts; Finerman's Firm Owns Russell 2000 Puts; Finerman's Firm And Finerman Own (HD), (C), (FLS), (KALU)